

Precision Scouts Against Cancer: Cloud-Clone Empowers Precision Tumor Diagnosis & Early Screening with R&D Technologies

*Core Challenge in Global Cancer Control:
The Critical Value of Early Screening &
Diagnosis*

HUSTON, TX, UNITED STATES, August 17, 2026 /EINPresswire.com/ -- A widespread global concern in oncology care is that most patients receive a late-stage cancer diagnosis, which severely limits overall survival rates and curative chances. Early screening, early diagnosis and early treatment constitute the core strategy to extend patient survival and improve cure rates. While surgery, radiotherapy and chemotherapy eliminate established lesions, and monoclonal [antibody](#) drugs act as targeted tumor killers, high-precision early tumor diagnostic technology serves as the frontline "precision scout" in the global fight against cancer.

With nearly 20 years of dedicated research in immunological research reagents, [Cloud-Clone](#) has built a fully self-developed end-to-end R&D platform and amassed a massive library of biological biomarkers. Covering the full workflow of tumor early screening mechanism research and targeted new drug development, Cloud-Clone stands as an indispensable core supplier delivering reliable diagnostic reagents for global precision oncology.



I. Focused on Unmet Clinical Demand for Early Screening: Standardized Quality Control Lays the Foundation for Accurate Diagnosis

Tumor biomarker testing is non-invasive, suitable for mass population screening, and enables

long-term dynamic monitoring of disease progression, making it a core tool for population health checks, clinical patient monitoring and postoperative recurrence risk alerting. Testing accuracy heavily relies on core raw materials including antigens, antibodies and assay kits. High-performance diagnostic reagents must simultaneously meet three strict criteria: high sensitivity to capture trace early pathological signals, high specificity to minimize false positive and false negative results, and superior stability to guarantee consistent data across long-term patient follow-up.

Cloud-Clone rigorously benchmarks all products against these three metrics and implements a refined full-process quality management system. The company holds three internationally recognized certifications: ISO9001:2015, ISO13485:2016 and ISO14001:2015. Every production stage, from raw material R&D to finished kit release, undergoes rigorous quality control, breaking the long-term market monopoly of imported diagnostic reagents worldwide.

At present, Cloud-Clone's tumor biomarker raw material portfolio covers more than ten high-incidence cancer types, including lung cancer, liver cancer, gastric cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, glioma, pancreatic cancer and melanoma. Its catalog features over 800 detectable biomarkers such as AFP, CEA, CA19-9, CA125, PSA, Her2 and EGFR, fully addressing diverse testing demands for clinical early screening and academic cancer research.

Figure 1 Cloud-Clone R&D researchers analyzing histopathological tissue sections

II. Authoritative Validation via Top-Tier Journals: Cloud-Clone Reagents Supported by Global Research Data

Backed by consistent superior product performance, Cloud-Clone reagents have contributed to more than 42,000 published research papers globally, with over 350 citations in world-renowned top journals including Cell, Nature and Science. The reliability of Cloud-Clone products is continuously validated by leading research teams across the globe, supporting landmark oncology research published in high-impact international journals:

1.The research team led by Academician He Fuchu at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences utilized Cloud-Clone HSP90 α ELISA kits for lung adenocarcinoma research, with findings published in Cell (Impact Factor = 38.637). Researchers at The First Affiliated Hospital of Zhengzhou University leveraged Cloud-Clone humanized antibodies to dissect tumor drug resistance mechanisms, publishing their work in Molecular Cancer (Impact Factor = 41.444).

2.Teams at Zhongnan Hospital of Wuhan University and New York University School of Medicine employed Cloud-Clone IL6 and Ntn1 reagent series to advance glioma and myeloma research respectively, with two independent studies simultaneously featured in Nature Medicine (Impact Factor = 32.621).

3.Researchers at Nanyang Technological University, Singapore, developed a synchronous monitoring protocol for renal injury during lung cancer chemotherapy using Cloud-Clone CYFRA21-1 and CEA kits, with results published in Nature Biomedical Engineering (Impact Factor = 26.6).

4.Groups at Maastricht University (the Netherlands) and The Second Affiliated Hospital of

Zhejiang University completed bladder and breast cancer research with Cloud-Clone ApoA1 and DCA reagents, publishing key data in Cell Metabolism (Impact Factor = 20.565).

5. Multiple universities and hospitals across Germany, Japan, the United States, Switzerland and the United Kingdom adopted Cloud-Clone reagents to conduct studies on colorectal, prostate, gastric and pancreatic cancer, yielding numerous publications in high-impact journals such as Nature Communications and Clinical Cancer Research.

Additionally, leading research institutions including Renji Hospital, Shanghai Jiao Tong University, Nanjing University and Tianjin Medical University Cancer Institute & Hospital widely deploy Cloud-Clone reagents to produce high-level scientific outputs. Cloud-Clone products are now adopted by over 75% of top academic research institutions across Europe and North America, with extensive authoritative research data verifying the consistent performance of its reagent portfolio.

III. Persistent Original R&D: Full-Chain Technology Empowers Global Scientific Research & Anti-Cancer Innovation

Guided by the core mission of advancing human health worldwide, Cloud-Clone continuously addresses unmet testing demands in basic research and clinical oncology by investing heavily in core technology development. Supported by four proprietary self-built technical platforms — small molecule modification, high-efficiency recombinant protein expression, high-specificity monoclonal antibody screening and high-throughput multiplex cytokine assay development — the company has established a comprehensive product portfolio:

- Over 18,000 recombinant proteins
 - More than 27,000 antibodies
 - Over 10,000 ELISA kits
 - 560+ primary cell products
 - More than 350 multiplex biomarker detection panels
- Covering a total of over 8,000 unique biological targets.

Cloud-Clone iteratively launches specialized product variants tailored to diverse application scenarios, including high-sensitivity kits, rapid detection kits and kits optimized for minute sample volumes. The full product line delivers stable performance for processing rare, low-volume clinical specimens, high-throughput research sample screening, and capturing faint low-abundance early tumor molecular signals, effectively resolving core pain points in global diagnostic testing workflows.

Thanks to consistent premium quality and integrated one-stop technical support, Cloud-Clone products are supplied to clients across all continents, securing long-term procurement partnerships with leading global pharmaceutical enterprises and research institutes such as Pfizer (USA), MD Anderson Cancer Center, Russian Academy of Sciences and Max Planck Institute (Germany).

Cloud-Clone also maintains deep strategic layout in novel anti-cancer therapeutic drug development. Driven by rapid advances in precision medicine, monoclonal antibodies, antibody-drug conjugates (ADCs) and bispecific antibodies have become mainstream therapeutic R&D directions. Compared with traditional systemic treatments, antibody drugs

deliver strong tumor targeting with reduced systemic toxic side effects, and significantly boost therapeutic efficacy when combined with radiotherapy, chemotherapy or immune checkpoint inhibitors.

Cloud-Clone's proprietary monoclonal antibody raw material development platform generates binders specific to tumor-exclusive targets including TROP2, ROR1, Nectin-4, HER3 and 5T4, minimizing off-target damage to healthy tissues. The reagents demonstrate broad compatibility and flexibility, supporting personalized therapeutic strategies of stratified treatment for patients with identical or distinct cancer types, and produce synergistic efficacy when paired with multiple treatment regimens.

After two decades of sustained technical breakthroughs, Cloud-Clone has overcome longstanding overseas technical barriers and built a fully independent, controllable full-value industrial chain spanning antigen design, recombinant protein expression, monoclonal antibody generation, assay kit development, large-scale manufacturing and standardized quality inspection, setting a global benchmark for high-quality bioreagent manufacturing.

Figure 2 Cloud-Clone laboratory technician observing cell cultures under inverted microscope

Conclusion

Diagnostics form the foundation of global anti-cancer efforts. Every accurate early screening test delivers an extra layer of protection for patient survival. Tumor diagnostic testing runs through the full patient journey: high-risk population screening, personalized therapeutic regimen design, and long-term surveillance for postoperative cancer recurrence.

Moving forward, Cloud-Clone will continue to deepen its expertise in precision tumor detection. The company will leverage proprietary core technologies to upgrade diagnostic reagents, accelerate the global popularization of accessible early cancer screening and advance targeted anti-cancer drug development, delivering world-class biotechnology solutions to support human health initiatives across all regions of the globe.

About Cloud-Clone Corp.

Cloud-Clone Corp. is dedicated to the development and production of high-quality immunoassay reagents and detection solutions. With a focus on antibody engineering, multiplex assay development, and cross-platform compatibility, the company provides research tools designed to support precision medicine and advanced biomedical investigation globally. Our core products and services include the research and development of proteins, antibodies, ELISA kits, primary cells, and multiplex cytokine assay kits, as well as professional CRO services to fully meet the diverse needs of biomedical research and related fields.

For more information about Cloud-Clone Corp, visit www.cloud-clone.com.

CLOUD-CLONE CORP.(CCC)

Tel: 001-832-538-0970, 0086-27-8425-9552

Email: mail@cloud-clone.com, sales@cloud-clone.us

Visit us on social media:

LinkedIn: <https://www.linkedin.com/company/cloud-clone-corp/>

Instagram: <https://www.instagram.com/cloudclonecorp2023/>

TickTok: <https://www.tiktok.com/@cloudclonecorp2026>

SuKi Duan

CLOUD-CLONE CORP.WUHAN

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[TikTok](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/934697296>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.